Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increa...
Main Authors: | Tinsley, J, Fairclough, R, Storer, R, Wilkes, F, Potter, A, Squire, SE, Powell, D, Cozzoli, A, Capogrosso, R, Lambert, A, Wilson, F, Wren, S, De Luca, A, Davies, K |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Public Library of Science
2011
|
Registos relacionados
-
Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
Por: Jonathon M Tinsley, et al.
Publicado em: (2011-05-01) -
Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
Por: Tinsley, J, et al.
Publicado em: (2013) -
Up-regulation of utrophin alleviates the dystrophic phenotype in the mdx mouse heart
Por: Sang, E, et al.
Publicado em: (2000) -
Non-toxic ubiquitous overexpression of utrophin in the mdx mouse.
Por: Fisher, R, et al.
Publicado em: (2000) -
Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.
Por: Fisher, R, et al.
Publicado em: (2001)